References
- Scott KR, Barrett AM. Dementia syndromes: evaluation and treatment. Expert Rev Neurother 2007;7:407-22
- Simmons BB, Hartmann B, Dejoseph D. Evaluation of suspected dementia. Am Fam Physician 2011;84:895-902
- Alzheimer’s and Dementia in France. Chicago, IL. Available at: http://www.alz.org/fr/dementia-alzheimers-france.asp [Last accessed 19 December 2016]
- Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology Minneapolis 2000;54(11;Suppl5):S4-S9
- Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 2009;11:111-28
- Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112-17
- Wimo A, Reed CC, Dodel R, et al. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer’s disease in three European countries – study design and baseline findings. J Alzheimers Dis 2013;36:385-99
- Ball M, Braak H, Coleman P, et al. Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. Neurobiol Aging 1997;18:S1-S2
- Braak H, Braak E. Evolution of the neuropathology of Alzheimers disease. Acta Neurol Scand Suppl 1996;165:3-12
- Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathological assessment of Alzheimer’s disease. Neurology 1991;41:479-86
- Small GW. Diagnostic issues in dementia: neuroimaging as a surrogate marker of disease. J Geriatr Psychiatry Neurol 2006;19:180-5
- Weimer DL, Sager MA. Early identification and treatment of Alzheimer’s disease: social and fiscal outcomes. Alzheimers Dement 2009;5:215-26
- Wimo A, Winblad B, Stoffler A, et al. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer’s disease. Pharmacoeconomics 2003;21:327-40
- Guo S, Getsios D, Hernandez L, et al. Florbetaben PET in the early diagnosis of Alzheimer’s disease: a discrete event simulation to explore its potential value and key data gaps. Int J Alzheimer’s Dis 2012; Art. No.: CD005593
- Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006; Art. No.: CD003154
- McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006; http://www.has-sante.fr/portail/jcms/c_1118365/en/aricept-19-10-2011-avis-ct-10755
- French National Authority for Health (Haute Autorite de sante, HAS). Transparency Committee Opinion – Aricept. [In French.] Available at: http://www.has-sante.fr/portail/jcms/c_1117852/en/aricept [Last accessed 18 April 2013]
- Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 2010;9:119-28
- Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011;305:275-83
- Woolley J, Khan B, Murthy N, et al. The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. J Clin Psychiatry 2011;72:126-33
- Schoonenboom NS, Reesink FE, Verwey NA, et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 2012;78:47-54
- Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol 2009;65:403-13
- Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009;66:382-9
- Laforce R, Rabinovici GD. Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. Alzheimers Res Ther 2011;3:31
- Amyvid: EPAR – Product Information. EU: European Medicines Agency (EMA). Available at: http://ec.europa.eu/health/documents/community-register/2013/20130114124958/anx_124958_en.pdf [Last accessed 18 April 2013]
- Alzheimer’s Disease – Donepezil, Rivastigmine, Galantamine and Memantine (Review): Appraisal Consultation Document. London, England: National Institute for Clinical Excellence. Available from: http://www.nice.org.uk/guidance/index.jsp?action=article&r=true&o=33723 [Last accessed 9 July 2012]
- French National Authority for Health (Haute Autorite de sante, HAS). Alzheimer’s Disease and Related Conditions – Diagnosis and Treatment [Maladie d’Alzheimer: Diagnostic et Prise en Charge]. [In French.] Available at: http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-01/reco2clics_maladie_d_alzheimer_et_maladies_apparentees_diagnostic_et_prise_en_charge_2012-01-16_14-17-37_906.pdf [Last accessed 15 August 2012]
- Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) – explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 2013;16:231-50
- Pradier C, Sakarovitch C, Le Duff F, et al. The Mini Mental State Examination at the time of Alzheimer’s disease and related disorders diagnosis, according to age, education, gender and place of residence: a cross-sectional study among the French National Alzheimer database. PLoS One 2014;9:e103630
- Cortes F, Nourhashemi F, Guerin O, et al. Prognosis of Alzheimer’s disease today: a two-year prospective study in 686 patients from the REAL-FR Study. Alzheimers Dement 2008;4:22-9
- Grundman M, Pontecorvo MJ, Sallowa SP, et al. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord 2013;27:4-15
- Alpérovitcha A, Amouyelb P, Dartiguesc J-F, et al. Epidemiological studies on aging in France: from the Paquid study to the study of the Three Cities [Les études épidémiologiques sur le vieillissement en France: de l’étude Paquid à l’étude des Trois Cités]. [In French.] C R Biologies 2002;325:665-72
- Beach TG, Monsell SE, Phillips LE, et al. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. J Neuropathol Exp Neurol 2012;71:266-73
- Koopman K, Le Bastard N, Martin JJ, et al. Improved discrimination of autopsy-confirmed Alzheimer’s disease (AD) from non-AD dementias using CSF P-tau(181P). Neurochem Int 2009;55:214-18
- Roher AE, Maarouf CL, Sue LI, et al. Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer’s disease. Biomarkers 2009;14:493-501
- Cure S, Abrams K, Belger M, et al. Systematic literature review and meta-analysis of diagnostic test accuracy in Alzheimer’s disease and other dementia using autopsy as standard of truth. J Alzheimers Dis 2014;42:169-82
- Clark CM, Sheppard L, Fillenbaum GG, et al. Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer’s Disease. Arch Neurol 1999;56:857-62
- Harris IA, Yong S, McEvoy L, et al. A prospective study of the effect of nursing home residency on mortality following hip fracture. ANZ J Surg 2010;80:447-50
- Lopez OL, Becker JT, Saxton J, et al. Alteration of a clinically meaningful outcome in the natural history of Alzheimer’s disease by cholinesterase inhibition. J Am Geriatr Soc 2005;53:83-7
- Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology 1989;39:1159-65
- Olichney JM, Galasko D, Salmon DP, et al. Cognitive decline is faster in Lewy body variant than in Alzheimer’s disease. Neurology 1998;51:351-7
- Wattmo C, Wallin AK, Londos E, et al. Risk factors for nursing home placement in Alzheimer’s disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment. Gerontologist 2011;51:17-27
- Getsios D, Blume S, Ishak KJ, et al. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer’s disease: a UK evaluation using discrete-event simulation. Pharmacoeconomics 2010;28:411-27
- Pastätter R, Uhl-Hochgräber K, Blankenburg M. PMD51 cost savings and improved utility through the use of florbetaben beta-amyloid PET imaging in dementia diagnosis. Value Health 2011;14:A253
- Getsios D, Blume S, Ishak KJ, et al. An economic evaluation of early assessment for Alzheimer’s disease in the United Kingdom. Alzheimers Dement 2012;8:22-30
- Pariente A, Pinet M, Moride Y, et al. Factors associated with persistence of cholinesterase inhibitor treatments in the elderly. Pharmacoepidemiol Drug Saf 2010;19:680-6
- Helmer C, Pasquier F, Dartigues JF. Epidemiology of Alzheimer disease and related disorders. Med Sci (Paris) 2006;22:288-96
- Vidal JS, Lacombe JM, Dartigues JF, et al. Memantine therapy for Alzheimer disease in real-world practice: an observational study in a large representative sample of French patients. Alzheimer Dis Assoc Disord 2008;22:125-30
- Bond M, Rogers G, Peters J, et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technol Assess 2012;16:1-470
- Biasutti M, Dufour N, Ferroud C, et al. Cost-effectiveness of magnetic resonance imaging with a new contrast agent for the early diagnosis of Alzheimer’s disease. PLoS One 2012;7:e35559
- Common Classification of Medical Acts: Social Security (Version 28) [Classification Commune des Actes Medicaux: Securite Sociale (Version 28)]. [In French.] France. Available at: http://www.ameli.fr/fileadmin/user_upload/documents/CCAM_V28.pdf [Last accessed 18 July 2013]
- Confederation of Medical Unions [Confédération des Syndicats Médicaux Français], 2011. National Convention Organizing the Relations Between the Liberal Doctors and the Sickness Insurance Signed on July 26, 2011 [Convention Nationale Organisant les Rapports Entre les Medecins Liberaux et L’assurance Maladie Signee le 26 Juillet 2011]. [In French.] Available at: http://www.csmf.org/upload/File/Conv_med/conv_med_annexes_110726.pdf [Last accessed 4 June 2013]
- WHO Collaborating Centre for Drug Statistics Methodology: ATC/DDD Index 2012. Oslo, Norway. Available at: http://www.whocc.no/atc_ddd_index/ [Last accessed 15 August 2012]
- Health Insurance: Drug Base and Tariff Information [l’Assurance Maladie: Base des Médicaments et Informations Tarifaires]. [In French.] France. Available at: http://www.codage.ext.cnamts.fr/codif/bdm_it/index.php?p_site=AMELI [Last accessed 30 July 2012]
- Draft Conventional Text ANNEXES [Projet de texte conventionnel ANNEXES]. [In French.] France: Federation des Medecins de France. Updated 20 July 2011. Available at: http://www.fmfpro.com/convention/projet-de-texte-conventionnel-version-du-20-juillet-2011-en-seance.html [Last accessed 15 August 2012]
- Montpellier CD. Repository of non-nomenclature codes [Montpellier Cd. Référentiel des codes hors nomenclature] (RHN) Version 4.1. [In French.] France. Updated 7 September 2012. Available at: http://www.chu-montpellier.fr/publication/inter_pub/R300/A11181/RHN.V4.1.pdf [Last accessed 11 July 2013]
- Maladie LA. Nationale de Biologie, Base de Reference (2012). France. Available at: http://www.codage.ext.cnamts.fr/codif/nabm//telecharge/index_tele.php?p_site= [Last accessed 15 August 2012]
- Barbieri M, Drummond M, Willke R, et al. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health 2005;8:10-23
- French National Authority for Health (Haute Autorite de sante [HAS]). Choices in Methods for Economic Evaluation. Updated October 2012. Available at: http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-10/choices_in_methods_for_economic_evaluation.pdf [Last accessed 29 July 2013]
- Helmer C, Joly P, Letenneur L, et al. Mortality with dementia: results from a French prospective community-based cohort. Am J Epidemiol 2001;154:642-8
- Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol 2012;11:669-78
- McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939-44
- Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-95
- Neumann PJ, Kuntz KM, Leon J, et al. Health utilities in Alzheimer’s disease: a cross-sectional study of patients and caregivers. Med Care 1999;37:27-32
- High Authority of Health: ALD n° 15 – Alzheimer’s disease and other dementias [Haute Autorité De Santé: ALD n° 15 – Maladie d’Alzheimer et autres démences]. [In French.] France. Updated 9 July 2009. Available at: http://www.has-sante.fr/portail/jcms/c_820000/ald-n-15-maladie-d-alzheimer-et-autres-demences [Last accessed 15 August 2012]
- General Nomenclature of Nursing Professional Acts [Nomenclature General des actes Professionnels Infirmiers]. [In French.] Available at: http://www.infirmiers.com/pdf/ngapi.pdf [Last accessed 27 April 2012]
- McMahon PM, Araki SS, Neumann PJ, et al. Cost-effectiveness of functional imaging tests in the diagnosis of Alzheimer disease. Radiology 2000;217:58-68
- Weycker D, Taneja C, Edelsberg J, et al. Cost-effectiveness of memantine in moderate-to-severe Alzheimer’s disease patients receiving donepezil. Curr Med Res Opin 2007;23:1187-97
- Lee CP, Chertow GM, Zenios SA. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health 2009;12:80-7
- Central Intelligence Agency (Office of Public Affairs). World Factbook Page on France, Section: Economy – overview. Washington, DC. Available at: https://www.cia.gov/library/publications/the-world-factbook/geos/fr.html [Last accessed 13 June 2013]
- Schubert CC, Boustani M, Callahan CM, et al. Acute care utilization by dementia caregivers within urban primary care practices. J Gen Intern Med 2008;23:1736-40
- Reed C, Argimon J, Belger M, et al. Health care resource use and cost in Alzheimer’s disease in three European countries – baseline findings of the Geras study. Abstract number PND48. ISPOR 15th Annual European Congress, 2012
- Wilkosz PA, Seltman HJ, Devlin B, et al. Trajectories of cognitive decline in Alzheimer’s disease. Int Psychogeriatr 2010;22:281-90
- Neumann PJ, Cohen JT, Hammitt JK, et al. Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Econ 2012;21:238-51
- Nichols LO, Martindale-Adams J, Burns R, et al. Translation of a dementia caregiver support program in a health care system – REACH VA. Arch Intern Med 2011;171:353-9
- Wray LO, Shulan MD, Toseland RW, et al. The effect of telephone support groups on costs of care for veterans with dementia. Gerontologist 2010;50:623-31
- Brodaty H. Meaning and measurement of caregiver outcomes. Int Psychogeriatr 2007;19:363-81
- Kannan H, Bolge SC, Del Valle M, et al. The association between Alzheimer’s disease symptom severity and caregiver outcomes: a cross-sectional study. Prim Care Companion CNS Disord 2011;13:e1-e8